Epithelial ovarian cancer: Focus on genetics and animal models

Cell Cycle

Volumn 8, Issue 5, 2009, Pages 731-735

  Shan, Weiwei ^a   Liu, Jinsong ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Epithelial ovarian cancer; Genetically modified animal models; Ovarian epithelial cells; Review; Tumorigenesis

Indexed keywords

ABC TRANSPORTER; B RAF KINASE; K RAS PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; RETINOBLASTOMA PROTEIN;

CARCINOGENESIS; CELL DIFFERENTIATION; ENDOMETRIOID CARCINOMA; EPITHELIUM CELL; EXPERIMENTAL ANIMAL; GENE MUTATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MICROARRAY ANALYSIS; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; REVIEW; RODENT;

ANIMALIA; RODENTIA;

EID: 62449340297     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.8.5.7848     Document Type: Review

References (44)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Feeley KM, Wells M. Precursor lesions of ovarian epithelial malignancy. Histopathology 2001; 38:87-95.
3. Roh MH, Kindelberger D, Crum CP. Serous Tubal Intraepithelial Carcinoma and the Dominant Ovarian Mass: Clues to Serous Tumor Origin? Am J Surg Pathol 2008.
4. Bjorkholm E, Pettersson F, Einhorn N, Krebs I, Nilsson B, Tjernberg B. Long-term follow-up and prognostic factors in ovarian carcinoma. The radiumhemmet series 1958 to 1973. Acta Radiol Oncol 1982; 21:413-9.
5. Hogberg T, Carstensen J, Simonsen E. Treatment results and prognostic factors in a population-based study of epithelial ovarian cancer. Gynecol Oncol 1993; 48:38-49.
6. Sorbe B, Frankendal B, Veress B. Importance of histologic grading in the prognosis of epithelial ovarian carcinoma. Obstet Gynecol 1982; 59:576-82.
7. Foulkes WD. Of mice and women. Cancer Cell 2002; 1:11-2.
8. Rosen DG, Yang G, Liu G, Mercado-Uribe I, Chang B, Xiao X, et al. Ovarian Cancer: Pathology, Biology and Disease Models. Frontier in Biosciences 2009; 14:2089-102.
9. Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, et al. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003; 63:1389-97.
10. Shih Ie M, Kurman RJ. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164:1511-8.
11. Singer G, Oldt R, 3rd, Cohen Y, Wang BG, Sidransky D, Kurman RJ, et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma. J Natl Cancer Inst 2003; 95:484-6.
12. Landen CN Jr, Birrer MJ, Sood AK. Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol 2008; 26:995-1005.
13. Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol 2004; 28:496-504.
14. Okuda T, Otsuka J, Sekizawa A, Saito H, Makino R, Kushima M, et al. p53 mutations and overexpression affect prognosis of ovarian endometrioid cancer but not clear cell cancer. Gynecol Oncol 2003; 88:318-25.
15. Skirnisdottir I, Seidal T, Karlsson MG, Sorbe B. Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II. Int J Oncol 2005; 26:177-83.
16. Obata K, Morland SJ, Watson RH, Hitchcock A, Chenevix-Trench G, Thomas EJ, et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res 1998; 58:2095-7.
17. Sato N, Tsunoda H, Nishida M, Morishita Y, Takimoto Y, Kubo T, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res 2000; 60:7052-6.
18. Moreno-Bueno G, Gamallo C, Perez-Gallego L, de Mora JC, Suarez A, Palacios J. beta-Catenin expression pattern, beta-catenin gene mutations, and microsatellite instability in endometrioid ovarian carcinomas and synchronous endometrial carcinomas. Diagn Mol Pathol 2001; 10:116-22.
19. Sagae S, Kobayashi K, Nishioka Y, Sugimura M, Ishioka S, Nagata M, et al. Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res 1999; 90:510-5.
20. Wright K, Wilson P, Morland S, Campbell I, Walsh M, Hurst T, et al. beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer 1999; 82:625-9.
21. Cheng W, Liu J, Yoshida H, Rosen D, Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005; 11:531-7.
22. Ma L, Benson GV, Lim H, Dey SK, Maas RL. Abdominal B (AbdB) Hoxa genes: regulation in adult uterus by estrogen and progesterone and repression in mullerian duct by the synthetic estrogen diethylstilbestrol (DES). Dev Biol 1998; 197:141-54.
23. Jull JW. Ovarian tumorigenesis. Methods Cancer Res 1973; 3:131-86.
24. Kato T, Yakushiji M, Tsumawaki A, Ide K, Hirose N, Araki S, et al. Studies on experimental formation of ovarian tumors. Kurume Med J 1975; 22:169-76.
25. Adams AT, Auersperg N. Transformation of cultured rat ovarian surface epithelial cells by Kirsten murine sarcoma virus. Cancer Res 1981; 41:2063-72.
26. Godwin AK, Testa JR, Handel LM, Liu Z, Vanderveer LA, Tracey PA, et al. Spontaneous transformation of rat ovarian surface epithelial cells: association with cytogenetic changes and implications of repeated ovulation in the etiology of ovarian cancer. J Natl Cancer Inst 1992; 84:592-601.
27. Testa JR, Getts LA, Salazar H, Liu Z, Handel LM, Godwin AK, et al. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity. Cancer Res 1994; 54:2778-84.
28. Roby KF, Taylor CC, Sweetwood JP, Cheng Y, Pace JL, Tawfik O, et al. Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000; 21:585-91.
29. Kido M, Shibuya M. Isolation and characterization of mouse ovarian surface epithelial cell lines. Pathol Res Pract 1998; 194:725-30.
30. Kleihues P, Schauble B, zur Hausen A, Esteve J, Ohgaki H. Tumors associated with p53 germline mutations: a synopsis of 91 families. Am J Pathol 1997; 150:1-13.
31. Flesken-Nikitin A, Choi KC, Eng JP, Shmidt EN, Nikitin AY. Induction of carcinogenesis by concurrent inactivation of p53 and Rb1 in the mouse ovarian surface epithelium. Cancer Res 2003; 63:3459-63.
32. Coppola D, Saunders B, Fu L, Mao W, Nicosia SV. The insulin-like growth factor 1 receptor induces transformation and tumorigenicity of ovarian mesothelial cells and downregulates their Fas-receptor expression. Cancer Res 1999; 59:3264-70.
33. Gregoire L, Rabah R, Schmelz EM, Munkarah A, Roberts PC, Lancaster WD. Spontaneous malignant transformation of human ovarian surface epithelial cells in vitro. Clin Cancer Res 2001; 7:4280-7.
34. Maines-Bandiera SL, Kruk PA, Auersperg N. Simian virus 40-transformed human ovarian surface epithelial cells escape normal growth controls but retain morphogenetic responses to extracellular matrix. Am J Obstet Gynecol 1992; 167:729-35.
35. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, et al. A genetically defined model for human ovarian cancer. Cancer Res 2004; 64:1655-63.
36. Gong Z, Zhu J, Yu G, Zou H. Disruption of nifA gene influences multiple cellular processes in Sinorhizobium meliloti. J Genet Genomics 2007; 34:783-9.
37. Orsulic S, Li Y, Soslow RA, Vitale-Cross LA, Gutkind JS, Varmus HE. Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002; 1:53-62.
38. Yang DH, Fazili Z, Smith ER, Cai KQ, Klein-Szanto A, Cohen C, et al. Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background. Am J Pathol 2006; 169:258-67.
39. Fazili Z, Sun W, Mittelstaedt S, Cohen C, Xu XX. Disabled-2 inactivation is an early step in ovarian tumorigenicity. Oncogene 1999; 18:3104-13.
40. Xu XX, Yi T, Tang B, Lambeth JD. Disabled-2 (Dab2) is an SH3 domain-binding partner of Grb2. Oncogene 1998; 16:1561-9.
41. Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005; 11:63-70.
42. Wu R, Hendrix-Lucas N, Kuick R, Zhai Y, Schwartz DR, Akyol A, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007; 11:321-33.
43. Crum CP, Drapkin R, Kindelberger D, Medeiros F, Miron A, Lee Y. Lessons from BRCA: The tubal fimbria emerges as an origin for pelvic serous cancer. Clin Med Res 2007; 5:35-44.
44. Medeiros F, Muto MG, Lee Y, Elvin JA, Callahan MJ, Feltmate C, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006; 30:230-36.